<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Forest Laboratories</title>
	<atom:link href="http://www.stockbloghub.com/tag/forest-laboratories/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(FRX) Forest Laboratories Presents Encouraging Data</title>
		<link>http://www.stockbloghub.com/2009/09/14/frx-forest-laboratories-presents-encouraging-data/15099</link>
		<comments>http://www.stockbloghub.com/2009/09/14/frx-forest-laboratories-presents-encouraging-data/15099#comments</comments>
		<pubDate>Mon, 14 Sep 2009 17:32:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Forest Laboratories]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15099</guid>
		<description><![CDATA[We are pleased to hear that Forest Laboratories (FRX) presented encouraging data from its phase III trial of ceftaroline for the treatment of community-acquired pneumonia [CAP] in hospitalized patients. The company presented new data from two multicenter studies – FOCUS 1 and FOCUS 2 – at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco. In addition to CAP, ceftaroline is also being studied for complicated skin and skin structure infections (cSSSI) caused by gram-positive bacteria. The randomized, double-blind trial compared ceftaroline with ceftriaxone in hospitalized adult patients with moderate to severe CAP. Following both the trials, it was found that patients treated with ceftaroline demonstrated a better cure rate (84.3%) compared to those treated with ceftriaxone (77.7%). In addition, the overall microbiological response rate in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/14/frx-forest-laboratories-presents-encouraging-data/15099/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Johnson &amp; Johnson Responds to FDA Questions on Antibiotic Drug Trials</title>
		<link>http://www.stockbloghub.com/2009/09/02/jnj-johnson-johnson-responds-to-fda-questions-on-antibiotic-drug-trials/14144</link>
		<comments>http://www.stockbloghub.com/2009/09/02/jnj-johnson-johnson-responds-to-fda-questions-on-antibiotic-drug-trials/14144#comments</comments>
		<pubDate>Wed, 02 Sep 2009 20:39:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals]]></category>
		<category><![CDATA[Forest Laboratories]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[Viropharma Incorporated]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14144</guid>
		<description><![CDATA[We are pleased to hear that the US Food and Drug Administration (FDA) has accepted Johnson &#38; Johnson’s (JNJ) response on clinical trial-related issues. Last month, the agency had warned the company for not maintaining proper records during the trial of ceftobiprole, a broad-spectrum antibiotic for the treatment of complicated skin infections and nosocomial pneumonia. J&#38;J had licensed the drug from Swiss drugmaker Basilea Pharmaceuticals in 2005. The issue must be resolved for the drug to be approved. The new drug application for ceftobiprole has been pending since May 2007. The approval is getting delayed since protocol-related issues have been present from the initial stages. In November last year, the FDA issued a Complete Response letter stating that it could not approve the new drug application at that time as ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/02/jnj-johnson-johnson-responds-to-fda-questions-on-antibiotic-drug-trials/14144/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories Announced Encouraging Data on Daxas</title>
		<link>http://www.stockbloghub.com/2009/08/28/frx-forest-laboratories-announced-encouraging-data-on-daxas/13828</link>
		<comments>http://www.stockbloghub.com/2009/08/28/frx-forest-laboratories-announced-encouraging-data-on-daxas/13828#comments</comments>
		<pubDate>Sat, 29 Aug 2009 00:09:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Forest Laboratories]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13828</guid>
		<description><![CDATA[In a positive development yesterday, Forest Laboratories (FRX) and Nycomed announced that encouraging data from a phase III clinical trial of their lung drug was published in a prestigious medical journal. We are pleased to hear that the drug, Daxas (a phosphodiesterase, PDE 4 inhibitor), improved lung function and reduced exacerbations in chronic obstructive pulmonary disease (COPD). The placebo-controlled trials were carried out in 4,500 patients spanning 10 countries. It evaluated the treatment in two studies, each of which covered a time span of 12 months and 6 months. Results showed that Daxas reduced COPD attacks by 17% per patient every year compared with a placebo and improved the volume of air that patients breathe out each second, a measure known as FEV1 by 48 millilitres. Studies also showed additional ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/28/frx-forest-laboratories-announced-encouraging-data-on-daxas/13828/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PG) P&amp;G Finds Buyer for Drug Business</title>
		<link>http://www.stockbloghub.com/2009/08/24/pg-pg-finds-buyer-for-drug-business/13200</link>
		<comments>http://www.stockbloghub.com/2009/08/24/pg-pg-finds-buyer-for-drug-business/13200#comments</comments>
		<pubDate>Mon, 24 Aug 2009 21:22:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Consumer Goods]]></category>
		<category><![CDATA[Personal Products]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[Barclays plc]]></category>
		<category><![CDATA[BCS]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[Credit Suisse Group]]></category>
		<category><![CDATA[CS]]></category>
		<category><![CDATA[Forest Laboratories]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Co]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[PG]]></category>
		<category><![CDATA[Procter & Gamble Company]]></category>
		<category><![CDATA[SJM]]></category>
		<category><![CDATA[The J. M. Smucker Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13200</guid>
		<description><![CDATA[Warner Chilcott, a specialty drug maker, recently announced plans to acquire Procter &#38; Gamble Co.’s (PG) prescription drug business for about $3 billion. Last December, P&#38;G had announced its intention to restrict making new investments in the pharmaceutical division and divest its interest in the healthcare brands. It decided to focus more on over-the-counter products such as Pepto Bismol, Prilosec, Vicks cough medicines and other personal care brands. Management stated that the pressure from generics was also one of the reasons for it to consider divestiture of this business. Earlier in fiscal 2008, P&#38;G sold its Folgers coffee business to J.M. Smucker Inc. (SJM) and added beauty and grooming businesses to its portfolio. The company’s prescription drugs division comprises products such as Actonel for osteoporosis (which generates more than $1 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/24/pg-pg-finds-buyer-for-drug-business/13200/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest&#8217;s COPD Drug Disappoints</title>
		<link>http://www.stockbloghub.com/2009/08/20/frx-forests-copd-drug-disappoints-analyst-blog/12842</link>
		<comments>http://www.stockbloghub.com/2009/08/20/frx-forests-copd-drug-disappoints-analyst-blog/12842#comments</comments>
		<pubDate>Thu, 20 Aug 2009 18:02:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Forest Laboratories]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12842</guid>
		<description><![CDATA[Yesterday, Forest Laboratories (FRX) announced disappointing results from the mid-stage clinical trials of oglemilast, meant for chronic obstructive pulmonary disease (COPD) that usually affects smokers. The drug was being developed with Glenmark Pharmaceuticals S.A. (Switzerland), a wholly owned unit of India-based Glenmark Pharmaceuticals. The phase IIb trial was conducted to determine the proper dosage for the drug. The 12-week trial was conducted on 428 patients aged 40 years or more and who had been smokers for about ten years. Oglemilast failed to show any improvement compared to a placebo during the study which evaluated a once-daily dosage of the drug in three dosage strengths (200 mcg, 400 mcg and 800 mcg). All 428 patients were randomized to receive one of the three doses of oglemilast (n=320) or placebo (n=108) and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/20/frx-forests-copd-drug-disappoints-analyst-blog/12842/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

